Zepbound Patient Assistance for Low-Income: How to Get Tirzepatide at Reduced or No Cost

What Zepbound Costs Without Assistance

Zepbound entered the U.S. Market in late 2023 with a list price of $1,059.87 per 4-week supply. That figure has remained stable through 2026, placing tirzepatide among the most expensive branded anti-obesity medications available. For a patient paying out of pocket, that translates to roughly $13,780 per year before pharmacy markups or dispensing fees.

Why the Retail Price Stays High

Eli Lilly holds active patents on tirzepatide through at least 2036, which means no FDA-approved generic version exists today [1]. The dual GIP/GLP-1 receptor agonist mechanism is novel, and manufacturing injectable peptides at scale remains resource-intensive. These factors give Lilly pricing power that the company has so far exercised without significant reductions to the wholesale acquisition cost.

How the Price Compares

Wegovy (semaglutide 2.4 mg), the most direct competitor, carries a list price of approximately $1,349 per month [2]. Zepbound's positioning slightly below Wegovy is intentional. Still, both prices sit far beyond what most uninsured Americans can absorb. A 2024 KFF analysis found that fewer than 1 in 5 adults with obesity could afford branded GLP-1 medications at list price without financial hardship [3].

The Eli Lilly Patient Assistance Program (Lilly Cares)

Lilly Cares is Eli Lilly's long-running patient assistance foundation. It covers Zepbound along with dozens of other Lilly products. Patients who qualify receive their medication at no cost, shipped directly from a specialty pharmacy.

Eligibility Requirements

To qualify for Lilly Cares, applicants must meet all of the following criteria: they must be a U.S. Resident, they must lack prescription drug insurance that covers Zepbound (or have been denied coverage), and their household income must fall at or below 400% of the federal poverty level [4]. For a single individual in 2026, 400% FPL is approximately $62,400 per year. A household of four qualifies at roughly $129,600.

How to Apply

Applications require a prescriber signature, proof of income (such as a tax return or pay stub), and documentation of insurance denial if applicable. Processing typically takes 4 to 6 weeks. Once approved, patients receive a 90-day supply and must requalify annually. The program ships medication through a designated pharmacy, so patients cannot fill at their local retail pharmacy [4].

What Lilly Cares Does Not Cover

The program does not cover patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs. It also excludes patients whose commercial insurance covers Zepbound but who simply face high copays. Those patients should look instead at the Zepbound Savings Card program.

The Zepbound Savings Card for Commercially Insured Patients

Eli Lilly offers a separate commercial savings card that reduces out-of-pocket costs for patients with private insurance. Eligible patients pay as little as $25 per month for Zepbound, with Lilly covering up to a set annual maximum [5].

Eligibility and Limitations

The savings card is available to commercially insured patients whose plan covers Zepbound. Patients with government insurance (Medicare Part D, Medicaid, TRICARE, VA) are excluded. The card typically caps annual savings at a defined dollar amount, after which the patient reverts to their plan's standard cost-sharing. Lilly has periodically adjusted these caps, so patients should verify current terms directly at the Zepbound savings card portal.

When the Savings Card Falls Short

If a patient's insurer does not cover Zepbound at all, the savings card generally cannot be applied. This is the most common frustration. A 2025 IQVIA report estimated that only 40% to 50% of commercial plans included any GLP-1 receptor agonist for obesity on formulary [6]. Patients in this gap, insured but without coverage for the drug, may need to pursue a formulary exception or appeal.

Insurance Coverage: What to Expect in 2026

Coverage for anti-obesity medications has expanded since 2023, but it remains inconsistent. The patchwork depends on employer decisions, state mandates, and payer willingness to absorb GLP-1 costs.

Commercial Insurance

Large self-insured employers increasingly cover GLP-1s for weight management, driven by data showing downstream reductions in cardiovascular events. The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with obesity and established cardiovascular disease [7]. Although SELECT studied semaglutide rather than tirzepatide, the cardiovascular signal has encouraged payers to broaden obesity medication formularies.

Tirzepatide's own cardiovascular outcomes trial, SURPASS-CVOT, is ongoing, and positive results could accelerate formulary inclusion [8]. For now, patients should call the number on the back of their insurance card and ask specifically whether Zepbound (tirzepatide) is covered under the pharmacy benefit for the indication of obesity or weight management.

Medicare Part D

Medicare Part D has historically excluded anti-obesity medications. The Treat and Reduce Obesity Act, reintroduced in Congress multiple times, would change this if passed. As of May 2026, the act has not been signed into law [9]. Medicare beneficiaries cannot use the Zepbound Savings Card and are currently ineligible for Lilly Cares as well, leaving a significant coverage gap for adults 65 and older.

Medicaid

Medicaid coverage varies by state. Some states have begun covering GLP-1 receptor agonists for obesity under their preferred drug lists, while others restrict coverage to type 2 diabetes indications only. Patients on Medicaid should check their state's formulary or contact their managed care organization directly.

Compounded Tirzepatide as a Lower-Cost Alternative

Since 2023, 503B outsourcing pharmacies have offered compounded tirzepatide at prices averaging around $249 per month, roughly 75% less than brand Zepbound [10].

The FDA Regulatory Field

The FDA permitted compounding of tirzepatide while the drug appeared on the agency's drug shortage list. In late 2024 and into 2025, the FDA moved to remove tirzepatide from the shortage list, triggering legal challenges from compounding pharmacies. Court rulings have varied by jurisdiction. As of mid-2026, some 503B pharmacies continue to compound tirzepatide under specific regulatory conditions, but this field shifts frequently [11].

Quality and Safety Considerations

The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends FDA-approved formulations as first-line therapy, noting that "compounded peptides have not undergone the rigorous testing required for FDA approval, and patients should be counseled about potential differences in purity, potency, and sterility" [12]. Patients who pursue compounded tirzepatide should verify that their pharmacy holds current FDA 503B registration and follows cGMP standards.

How to Access Compounded Tirzepatide

Telehealth platforms and some brick-and-mortar clinics prescribe compounded tirzepatide. Patients typically pay out of pocket because insurance does not cover compounded versions. Pricing ranges from $150 to $400 per month depending on the pharmacy, dose, and supply duration.

Additional Assistance Pathways

Beyond manufacturer programs and compounding, several other routes can reduce Zepbound costs.

Prescription Discount Cards and Aggregators

GoodRx, RxSaver, and similar platforms sometimes list Zepbound discount pricing, though savings vary widely. These cards work best for patients paying cash at a retail pharmacy. Discounts of 10% to 20% off list price are typical, which still leaves the monthly cost near $850 to $950.

Nonprofit Patient Assistance Foundations

Organizations like NeedyMeds and the Patient Advocate Foundation maintain databases of assistance programs for high-cost medications. These nonprofits can also help patients draft insurance appeals and manage prior authorization denials [13].

Prior Authorization Appeals

If an insurer denies Zepbound coverage, patients have the right to appeal. The most effective appeals include a letter of medical necessity from the prescribing clinician, documentation of prior failed weight-loss interventions (behavioral therapy, other medications), and reference to FDA labeling and clinical trial outcomes. Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, has noted: "A well-documented appeal that cites the patient's specific comorbidities and the FDA-approved indication often succeeds on the first or second attempt" [14].

State-Level Mandates

A small but growing number of states have introduced legislation requiring insurers to cover FDA-approved anti-obesity medications. Patients should check whether their state has enacted or proposed such mandates, as this can change the appeal calculus entirely.

Clinical Evidence Supporting Zepbound Access

Cost discussions are inseparable from efficacy data. The stronger the clinical evidence, the more use patients and prescribers have in appeals and coverage decisions.

SURMOUNT-1

The SURMOUNT-1 trial (N=2,539) randomized adults with obesity (BMI ≥30, or ≥27 with at least one comorbidity) to tirzepatide 5 mg, 10 mg, or 15 mg versus placebo. At 72 weeks, mean weight loss was 15.0% (5 mg), 19.5% (10 mg), and 22.5% (15 mg), compared to 2.4% for placebo [15]. More than 1 in 3 participants on the 15 mg dose lost at least 25% of body weight.

SURMOUNT-2

SURMOUNT-2 (N=938) focused on adults with both obesity and type 2 diabetes. Tirzepatide 15 mg produced 14.7% mean weight loss at 72 weeks, along with a 2.1 percentage-point reduction in HbA1c [16]. These dual benefits strengthen the case for coverage among patients with metabolic comorbidities.

SURMOUNT-3 and SURMOUNT-4

SURMOUNT-3 examined tirzepatide after an initial intensive lifestyle intervention, and SURMOUNT-4 assessed weight maintenance after drug discontinuation. SURMOUNT-4 demonstrated that patients who continued tirzepatide maintained an additional 5.5% weight loss over 52 weeks, while those switched to placebo regained weight [17]. This finding underscores that tirzepatide is a long-term therapy, making cost sustainability a pressing concern for patients.

Step-by-Step: Getting Zepbound at Reduced Cost

The most efficient path depends on insurance status. Here is a decision framework.

If You Are Uninsured

1. Apply to Lilly Cares (income must be at or below 400% FPL).
2. While awaiting approval (4 to 6 weeks), ask your prescriber about compounded tirzepatide from a 503B pharmacy.
3. Use GoodRx or RxSaver to compare retail cash prices if you need a bridge supply.

If You Have Commercial Insurance

1. Check your formulary for Zepbound coverage.
2. If covered, activate the Zepbound Savings Card for copay reduction (as low as $25/month).
3. If denied, file a prior authorization with your prescriber's office.
4. If the prior authorization is denied, appeal with a letter of medical necessity citing SURMOUNT trial data and your clinical history.
5. If all appeals fail, evaluate whether Lilly Cares eligibility applies (you may qualify as "underinsured").

If You Have Medicare or Medicaid

1. Medicare: no current Part D coverage for anti-obesity drugs. Monitor the Treat and Reduce Obesity Act for legislative changes.
2. Medicaid: check your state formulary. Some states cover GLP-1s for obesity; others restrict to diabetes.
3. In either case, compounded tirzepatide (if legally available) or manufacturer clinical trials may be the only affordable routes.

Monitoring Costs Beyond the Drug Itself

Zepbound treatment involves more than the medication price. Patients should budget for prescriber visits (typically every 3 to 6 months), baseline and follow-up labs (lipid panel, HbA1c, metabolic panel), and potential management of gastrointestinal side effects. Most insurance plans cover these visit and lab costs even when they do not cover the drug itself.

The SURMOUNT-1 trial reported that 26% of participants on tirzepatide 15 mg experienced nausea and 18% experienced diarrhea, most commonly during dose titration [15]. These side effects occasionally require anti-nausea medication or temporary dose reduction, adding modest costs during the first 2 to 3 months.

Patients enrolled in Lilly Cares should confirm whether the program covers all available Zepbound dose strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg), as titration through multiple strengths is standard during the first 20 weeks of treatment [18].